Otrivin Adult Nasal Drops

Go To

Decongestant effects
Rapid long-lasting effect
Moisturising effects
Recommend Otrivin Adult Nasal Drops
Product details

Nasal decongestant with soothing and moisturising effects^1-4

Otrivin Adult Nasal Drops is recommended for active, busy individuals who need immediate relief of nasal congestion, with soothing and moisturising effects to prevent dryness and irritations of the nasal mucosa.³

Immediate and long-lasting relief of nasal congestion

Otrivin Adult Nasal Drops provides rapid (within 2 to 5 minutes) and long-lasting (up to 12 hours) relief of nasal congestion with improvement in nasal airflow.^1,2

Xylometazoline with hypromellose and sorbitol: Unblocking with soothing and moisturising effects

Otrivin Adult nasal drops contains either 1 mg/ml xylometazoline with hypromellose and sorbitol.

Xylometazoline:⁴

Relieves nasal congestion due to colds, hay fever or other allergic rhinitis and sinusitis
Improves nasal airflow
Provides rapid (within 2 to 5 minutes) and long-lasting (up to 12 hours) relief of nasal congestion^1,2

Hypromellose and sorbitol:

Soothes and moisturises to prevent dryness and irritations of the nasal mucosa³

Recommend Otrivin Adult Nasal Drops to your patients for long-lasting relief from nasal congestion, with soothing and moisturising effects

Otrivin Adult Nasal Drops 1 ml contains 1 mg of xylometazoline hydrochloride.⁵Preservative: 0,011 % m/v benzalkonium chloride, hypromellose and sorbitol⁵

For patients who are looking for rapid and effective relief of nasal congestion, with soothing and moisturising effects.^1-4

Otrivin Adult Nasal Drops product details

Ingredients^1,5
Active ingredients:⁴

1 ml contains 1 mg of xylometazoline hydrochloride. Preservative: 0,011 % m/v benzalkonium chloride.⁵

Excipients: disodium edetate, disodium phosphate dodecahydrate, methylhydroxypropyl-cellulose, purified water, sodium chloride, sodium dihydrogen phosphate dihydrate, sorbitol 70 % (non-crystallising).⁵
Directions^1,5

Dosage and direction for use⁵:

OTRIVIN ADULT Nasal Drops:

(1 mg/ml) are for nasal administration only, in adults and children over 12 years of age: 2 to 3 drops of the 1 mg/ml solution into each nostril per application; a total of 3 applications a day is usually sufficient.
Warnings and Special Precautions:^1,5
OTRIVIN ADULT Nasal Drops should be used with caution in patients showing a strong reaction to sympathomimetic agents, as evidenced by signs of insomnia, dizziness as manifested by signs of insomnia, dizziness, tremor, cardiac dysrhythmias, or elevated blood pressure.

OTRIVIN ADULT Nasal Drops should be used with caution in patients with hypertension, cardiovascular disease, hyperthyroidism, diabetes mellitus, epistaxis, phaechromocytoma, prostatic hypertrophy, monoamine oxidase inhibitors (MAOI) treatment or who have received them in the last two weeks (see INTERACTIONS). Do not exceed the recommended dose, especially in children and in the elderly.

OTRIVIN ADULT Nasal Drops should not be used for more than ten consecutive days: prolonged or excessive use may cause rebound congestion and/or atrophy of the nasal mucosa

OTRIVIN ADULT Nasal Drops: long-lasting relief of nasal congestion, with soothing and moisturising effects^1-4,5

The Otrivin range

Find out how the Otrivin range can help your patients.

Find out more

Register Now

Join the Community

Patient care resources

Download resources for your patients.

Find out more

References

Eccles R et al. Am J Rhinol 2008; 22:491–496.
Clarke RW et al. Clin Otolaryngol Allied Sci 1995; 20:72–73.
Wade A, Weller P. Handbook of Pharmaceutical Excipients. 2nd ed. Washington and London: American Agent and The Pharmaceutical Press; 1994.
GSK Xylometazoline hydrochloride GDS v1.0; 26 Sept 2017; pages 2 & 5.
OTRIVIN ADULT Nasal Drops Patient Leaflet. March 2019.

S1 OTRIVIN ADULT Drops. Each 1 ml contains 1 mg of xylometazoline hydrochloride. Preservative: benzalkonium chloride 0.01 % m/v. Reg. no.: H/16.1/1382./p>

Applicant: GlaxoSmithKline Consumer Healthcare South Africa (Pty) Limited, 39 Hawkins Avenue, Epping Industria 1, Cape Town, 7460

Company reg. no.: 2014/173930/07. For full prescribing information refer to the professional information approved by the medicines regulatory authority.

Always read label prior to use.

For any further information, including safety and adverse reactions, please contact the GSK Hotline on 0800 007 018 or mystory.za@haleon.com.

Trademarks are owned by or licensed to the Haleon group of companies.

This site is intended for RSA healthcare professionals only.

© 2024 Haleon group of companies or its licensor. All rights reserved. Trademarks are owned by or licensed to the Haleon group of companies. This website is operated by Haleon South Africa (Pty) Ltd. 17 Muswell Road South, Block D, Wedgefield, Phase 2, Bryanston, Johannesburg, 2191, South Africa. Reg. No: 2014/173930/07. For any further information, including Human Safety Information (Adverse events/Product Quality Complaints) please contact the Haleon on 0800 007 018 or mystory.za@haleon.com. Always read the label, the leaflet or carton for full use instructions before use.

PM-ZA-NOBR-20-00013

PM-ZA-OTRI-21-00055Date of Preparation: October 2024